Cancer Research and Biotechnology AG

CRB has a clear vision to develop several unique oncology drugs, targeting aggressive cancers with high unmet medical need.


CRB is improving patient journey via an accelerated clinical regulatory pathway, aiming to reduce the burden of conventional treatments.

CRB aims to create cancer drugs accessible to every patient around the world.

Proven efficacy

CRB091 shows a strong efficacy in pre-clinical trials against metastatic melanoma cells and other deadly cancers

Proven safety

The small molecules of CRB091 are approved safe for human use, and do not induce toxicity in healthy cells

Fast path to
first in-human

Accelerated path to first in-human is based on decades of existing research

High impact
on patients

Visible path to first-in-human, today in preclinical studies of metastatic melanoma, triple-negative breast cancer, and colon cancer

Pipeline

CRB is dedicated to developing safe and efficient drugs for the treatment of aggressive cancers. The first drug, CRB091, is targeted against Metastatic Melanoma as first indication.

Other indications, including Triple-Negative Breast Cancer and Colorectal Cancer, are undergoing pre-clinical studies. They will follow a fast regulatory pathway to first in-human.

Drug Development
Discovery & Target Validation Preclinical Development Late Preclinical IND Human Use, Trial Phases
NTE ONCOLOGY: MM - CRB091
NTE ONCOLOGY: TNBC - CRB092
NTE ONCOLOGY: CRC - CRB093
NTE/NCE ONCOLOGY, other indications

TEAM

Meet the people behind the research

Our team is comprised of seasoned experts with DECADES OF EXPERIENCE in the Pharma industry. 

board of directors

KARI SARVANTO

CEO and Founder

Kai Karttunen

Co-Founder

executive Team

Kari Sarvanto

CEO AND FOUNDER

ALF BERNHARDT, MD

MEDICAL DIRECTOR

Sarah Haddad, PhD

Head of Science

Anna Saorin, PhD

Translational Scientist

Stage-dependent contribution

Kelly Austin, PhD, PPM

Head of US Regulatory Affairs

Franz Buchholzer, PhD

Regulatory Affairs

María Vázquez, PhD

Regulatory Advisor

Partners in Research and Development

Leading Service Providers

SIHAM CEBALLOS

PHD

SEPPO MÄKINEN

PhD Finance

STEPHEN PFLUGMACHER

Prof

TIMO MYÖHÄNEN

Prof

Team

KARI SARVANTO

CEO and Founder

Kai Karttunen

Chair and Co-Founder

Alf Bernhardt, MD

Medical DireCtor

Sarah Haddad, PhD

Head of Science

Anna Saorin, PhD

Translational Scientist

STAGE-DEPENDENT CONTRIBUTION

Research and
development,
Pre-Clinical

Drug
Development
and CMC

Regulatory
Affairs,
US

Clinical Affairs

Medical Affairs

figurenpop.de

The balance wheel, oscillating with metronomic precision at 28,800 beats per hour or more, acts as the guardian of time. This is the escapement, a miraculous piece of physics that allows energy to escape in measured, tiny increments, governing the relentless march of seconds, minutes, and hours.

Each screw head is polished to a mirror sheen, and every surface, even those never seen by the naked eye, is finished by the hand of a master craftsman. This obsessive dedication to beauty in the hidden places is not for vanity; it is a promise. A promise of quality, of integrity, and of a standard that refuses to compromise.